Renalytix logo

RenalytixNASDAQ: RNLX

Profile

Sector:

Healthcare

Country:

United States

IPO:

17 July 2020

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$12.44 M
-98%vs. 3y high
19%vs. sector
-vs. 3y high
-vs. sector
-105%vs. 3y high
9%vs. sector
-98%vs. 3y high
63%vs. sector

Price

regular market | Fri, 25 Oct 2024 13:30:00 GMT
$0.15-$0.00(-1.38%)

Dividend

No data over the past 3 years
$586.00 K$900.00 K
$586.00 K-$7.07 M

Analysts recommendations

Institutional Ownership

RNLX Latest News

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
globenewswire.com27 June 2024 Sentiment: POSITIVE

Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”

Medicare Issues Final Coverage Determination for kidneyintelX.dkd
globenewswire.com14 June 2024 Sentiment: POSITIVE

Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage

Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript
seekingalpha.com15 May 2024 Sentiment: POSITIVE

Renalytix Plc (NASDAQ:RNLX) will be hosting a conference call on May 15, 2024 at 8:30 AM ET to discuss the company's Q3 2024 financial results. Company representatives Peter DeNardo, James McCullough, James Sterling, and Howard Doran will be participating in the call. Analysts Dan Arias, Randy Baron, Mark Massaro, and Jens Lindqvist will also be in attendance. The operator will provide instructions for the call. Good morning, and thank you for joining the Renalytix conference call for the review of Third Quarter Fiscal Year 2024 Financial Results.

Renalytix slides by a third as funding moves front and centre
Proactive Investors15 February 2024 Sentiment: NEGATIVE

Renalytix dropped by more than a third as its latest interim results show more big losses and a shrinking cash pile. Losses are inevitable for an early-stage company such as Renalytix, which is developing diagnostics tools for kidney illness sufferers, but the scale seemingly is raising some alarms.

Renalytix rises on draft Medicare determination
Proactive Investors09 February 2024 Sentiment: POSITIVE

Shares in Renalytix PLC (AIM:RENX) jumped almost 30% on Friday after the diagnostics firm revealed a draft Medicare determination for its kidney function tests. The Centers for Medicare and Medicaid Services published the draft local coverage determination on Thursday, Renalytix said, relating to the use of its tests for those on the US state-funded medical insurance programme.

What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy Stock
Zacks Investment Research16 October 2023 Sentiment: POSITIVE

Renalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Renalytix sinks to near year low despite news of strengthening US patents
Proactive Investors06 October 2023 Sentiment: NEGATIVE

Renalytix PLC (AIM:RENX) shares fell 12% to 46.09p after it said newly allowed US patents further strengthen the core intellectual property underpinning its KidneyIntelX blood test technology. The US Patent Office issued a new notice of allowance of claims surrounding the biomarkers sTNFR1 and sTNFR2 used in the kidneyintelX.dkd test.

Renalytix AI PLC Sponsored ADR (RNLX) Loses -44.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research05 October 2023 Sentiment: POSITIVE

Renalytix AI PLC Sponsored ADR (RNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Renalytix surges 28% Medicaid news
Proactive Investors03 October 2023 Sentiment: POSITIVE

Shares of Renalytix PLC (AIM:RENX) surged 28% in early trading after the Centers for Medicare & Medicaid Services (CMS) announced a price of $950 for the company's FDA-approved kidneyintelX.dkd test. The test, which uses artificial intelligence to predict risks for people with type 2 diabetes and chronic kidney disease, will be listed on the nationwide Clinical Laboratory Fee Schedule starting January 1, and the price will be locked in for at least three years.

Renalytix Plc (RNLX) Q4 2023 Earnings Call Transcript
Seeking Alpha29 September 2023 Sentiment: POSITIVE

Renalytix Plc (NASDAQ:RNLX ) Q4 2023 Earnings Conference Call September 28, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Thomas McLain - President James Sterling - Chief Financial Officer Conference Call Participants Christopher Glasper - Singer Capital Markets Mark Massaro - BTIG Jens Lindqvist - Investec Yi Chen - H.C. Wainwright Operator Good morning, and welcome to the Renalytix Conference Call to Review Fourth Quarter and Full-Year Fiscal 2023 Financial Results.

What type of business is Renalytix?

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

What sector is Renalytix in?

Renalytix is in the Healthcare sector

What industry is Renalytix in?

Renalytix is in the Health Information Services industry

What country is Renalytix from?

Renalytix is headquartered in United States

When did Renalytix go public?

Renalytix initial public offering (IPO) was on 17 July 2020

What is Renalytix website?

https://renalytix.com

Is Renalytix in the S&P 500?

No, Renalytix is not included in the S&P 500 index

Is Renalytix in the NASDAQ 100?

No, Renalytix is not included in the NASDAQ 100 index

Is Renalytix in the Dow Jones?

No, Renalytix is not included in the Dow Jones index

When was Renalytix the previous earnings report?

No data

When does Renalytix earnings report?

Next earnings report date is not announced yet